Lake Street analyst Chad Messer initiated coverage of Plus Therapeutics (PSTV) with a Buy rating and $2 price target Plus recently relaunched CNSide, a circulating tumor cell based diagnostic for leptomeningeal metastases, notes the analyst, who sees “huge synergies” pairing CNSide with Reyobiq, a targeted radiotherapy in development for CNS tumors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTV:
- Plus Therapeutics price target lowered to $1.50 from $3 at Maxim
- Plus Therapeutics: Underpenetrated CNSide Commercial Potential and Reyobiq Accelerated-Approval Upside Support Buy Rating into 2026
- Plus Therapeutics price target lowered to $1 from $2 at H.C. Wainwright
- Plus Therapeutics Sharpens Focus on CNS Cancer Strategy
- Plus Therapeutics announces anticipated milestones for FY26